Fig. 3: Calibration of the virtual population to the viral load time course from Blaze-1 Ph3 trial of bamlanivimab and etesevimab. | npj Systems Biology and Applications

Fig. 3: Calibration of the virtual population to the viral load time course from Blaze-1 Ph3 trial of bamlanivimab and etesevimab.

From: A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions

Fig. 3

A Mean of the virtual population (N = 502) for the simulated placebo (PBO) group and the 2800 mg bamlanivimab + 2800 mg etesevimab simulated treated group matching the mean trial data from the observed Blaze-1 Ph3 placebo group and the 2800 mg bamlanivimab + 2800 mg etesevimab treated group. B log10 reduction in viral load from baseline at day 7 after treatment administration in the observed Blaze-1Ph 3 trial (blue) and the simulated the 2800 mg bamlanivimab + 2800 mg etesevimab treated group. Error bars represent the 95% confidence interval in the mean for clinical trial observations and the range of observations in the simulated virtual population. Violin plots are indicative of 99% prediction interval of mean from 1000 bootstrapped samples of the virtual population. Data extracted from ref. 22.

Back to article page